DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02928614

BIO-LOSEIT-II

CompletedPhase 4

Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance

Biomarkers in Obese Patients With Knee Osteoarthritis Following Long-term Weight Maintenance

Lead sponsor

Henrik Gudbergsen

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

150

estimated

Study population

Obesity / overweight, Osteoarthritis

Key I/E criterion

—

Primary endpoint

•Collagen II degradation fragment α-C2M

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02928614
Org study ID137.08

Timeline

Milestones

Study first posted2016-10-10estimated
Last update posted2019-03-25actual
Study start2016-11 (month precision)
Primary completion2019-02actual (month precision)
Study completion2019-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightOsteoarthritis

Eligibility

Who can enroll

Minimum age18 Years
Maximum age74 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Same as parent trial (NCT02905864)

Exclusion criteria

•Same as parent trial (NCT02905864)

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

6 endpoints
Primary/protocol endpoint/low confidence

Change in collagen II degradation fragment α-C2M

Time frame:Week 0 to 52

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in collagen II degradation fragment β-C2M

Time frame:Week 0 to 52

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in non-coding RNA type snoRNAs U38 and U48

Time frame:Week 0 to 52

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in miRNA-454

Time frame:Week 0 to 52

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in miRNA let-7e

Time frame:Week 0 to 52

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change in Nesfatin-1

Time frame:Week 0 to 52

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.